Biopharma

관련학술자료

Clinical and biomarker analyses of a phase II study of intratumoral tavokinogene telseplasmid (pIL-12) plus pembrolizumab in stage III/IV melanoma patients predicted to not respond to anti-PD-1SITC 2017

운영자 2018.09.10

첨부파일 | ONCS-SITC-POSTER-2017_-1.pdf 다운로드

Clinical and biomarker analyses of a phase II study of intratumoral tavokinogene telseplasmid (pIL-12) plus pembrolizumab in stage III/IV melanoma patients predicted to not respond to anti-PD-1SITC 2017